Bristol-Myers Squibb: Q2 Earnings Look Like An Inflection Point

Dair Sansyzbayev
8.95K Followers
(9min)

Summary

  • Bristol-Myers Squibb had a strong Q2 earnings report, backed by strong momentum in both legacy and new products.
  • The management has boosted its guidance for the remainder of 2024, enhancing confidence in the safety of the stock's stellar 5% dividend yield.
  • Seasonality trends suggest that the stock usually performs much better in the second half of a year.
  • My valuation analysis suggests that despite Friday's 11% spike in the share price, the stock is still nearly 40% undervalued.

Офис Bristol-Myers Squibb в Брисбене, штат Калифорния, США

JHVEPhoto/iStock Editorial via Getty Images

Investment thesis

Bristol-Myers Squibb (NYSE:BMY) has just recently released its Q2 earnings, which were very positively absorbed by the market as the stock delivered an 11% rally on Friday after the report went live.

This article was written by

8.95K Followers
I am a highly experienced Chief Financial Officer (CFO) with a strong background in the oilfield and real estate industries. With over a decade of experience in finance, I have led numerous complex due diligence efforts and M&A transactions, both domestically and internationally.In recent years, I have developed a keen interest in equity research and analysis of public companies. This interest has led me to render equity research services for a Dubai-based family office with over $20 million in assets under management (AUM). My expertise in finance allows me to provide valuable insights and recommendations to clients seeking to make informed investment decisions.I pride myself on my ability to analyze financial statements, evaluate market trends, and identify key drivers of growth in different industries. I am passionate about staying up-to-date on the latest developments and trends in the equity research industry, and I am always seeking to enhance my skills and knowledge through continuing education and professional development.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About BMY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on BMY

Related Stocks

SymbolLast Price% Chg
BMY
--